Myriad Genetics considers pharmaceutical spin-off
This article was originally published in Scrip
Executive Summary
Myriad Geneticsis considering separating its diagnostic and pharmaceutical businesses. The firm said it was exploring whether to spin off the pharmaceutical business, as well as other options to maximise shareholder value.